Behavior in children with Prader-Willi syndrome before and during growth hormone treatment: a randomized controlled trial and 8-year longitudinal study.

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a randomized controlled trial.

Behavior was measured annually by the Developmental Behavior Checklist for children with intellectual disability (DBC) and a Dutch questionnaire to evaluate social behavioral problems in children, the Children's Social Behavior Questionnaire (CSBQ).

Why It Was Studied

Information on behavior of children with Prader-Willi syndrome (PWS) and the effect of growth hormone (GH) treatment is scarce.

Parents report less problem behavior during GH treatment.

Who Took Part

The age groups tagged for this paper are young children, children and teenagers, both men and women.

How the Study Was Run

In design terms this was a randomized study.

Random assignment meant chance, not the researchers, decided who got Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and who got the comparison, which limits bias.

What Was Measured

Problem behavior measured by the DBC in children with PWS was similar compared to peers with comparable intellectual disability.

PubMed files the paper under topics including Human Growth Hormone, Intellectual Disability, Longitudinal Studies, Neurodevelopmental Disorders, Prader-Willi Syndrome, Problem Behavior and Surveys and Questionnaires.

What This Means in Plain Language

The paper is a randomized study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

The publication is from 2015 (European child & adolescent psychiatry), a journal based in Germany.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.